Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: A combined analysis of phase III randomized controlled trials.

Ball, Somedeb; Swarup, Sriman; Sultan, Anita; Thein, Kyaw Zin

Ball, Somedeb; Swarup, Sriman; Sultan, Anita; Thein, Kyaw Zin.

Affiliation

Ball S; Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. Electronic address: somedeb.ball@ttuhsc.edu.
Swarup S; Division of Hematology & Medical Oncology, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Sultan A; Division of Hematology & Medical Oncology, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Thein KZ; Division of Hematology & Medical Oncology, Texas Tech University Health Sciences Center, Lubbock, TX, USA.

Hematol Oncol Stem Cell Ther ; 14(3): 260-262, 2021 Sep.

Article in En | MEDLINE | ID: mdl-32413420

Subject(s)

Aminopyridines; Breast Neoplasms; Cardiac Conduction System Disease; Purines; Aminopyridines/adverse effects; Aminopyridines/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/epidemiology; Cardiac Conduction System Disease/chemically induced; Cardiac Conduction System Disease/epidemiology; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Metastasis; Purines/adverse effects; Purines/therapeutic use; Randomized Controlled Trials as Topic; Risk Factors

Key words

CDK 4/6 inhibitor; Meta-analysis; QT prolongation; Treatment discontinuation

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purines / Breast Neoplasms / Cardiac Conduction System Disease / Aminopyridines Limits: Female / Humans Language: En Journal: Hematol Oncol Stem Cell Ther Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google